Psyence Biomedical issues letter to shareholders

Dr. Neil Maresky, CEO, Psyence BioMed wrote in a letter to shareholders: “Over the past few months, Psyence BioMed has made meaningful progress across several fronts: clinical development, strategic positioning, regulatory compliance, and manufacturing stability… PBM has established a Steering Committee to guide the development of its early-phase study investigating the use of naturally sourced psilocybin for the treatment of Alcohol Use Disorder… Psyence BioMed’s partnership with PsyLabs continues to evolve as a cornerstone of our Ibogaine program… We are pleased to report that the Company has a strong cash balance of $11.4 million as at August 4, 2025, and is in a solid financial position with no outstanding debt… Regaining compliance with Nasdaq listing requirements marked an important milestone in our continued growth and credibility as a public company. Psyence BioMed successfully regained full compliance with all applicable Nasdaq continued listing requirements in June 2025… At Psyence BioMed, our commitment to long-term value is grounded in a clear strategic vision: to build a resilient, multi-asset biotechnology company that leads in the development of nature-derived psychedelic therapies. We are focused on advancing clinically validated, scalable solutions for complex mental health conditions where current treatments fall short.”